P40 (ΔNp63) is superior to p63 for the diagnosis of pulmonary squamous cell carcinoma

Modern Pathology

Volumn 25, Issue 3, 2012, Pages 405-415

  Bishop, Justin A ^a   Teruya Feldstein, Julie ^b   Westra, William H ^a   Pelosi, Giuseppe ^c   Travis, William D ^b   Rekhtman, Natasha ^b  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

adenocarcinoma; DNp63; p40; p63; squamous cell carcinoma

Indexed keywords

ISOPROTEIN; PROTEIN ANTIBODY; PROTEIN P40; PROTEIN P40 ANTIBODY; PROTEIN P63; PROTEIN P63 ANTIBODY 4A4; UNCLASSIFIED DRUG;

ANTIBODY LABELING; ARTICLE; CANCER DIAGNOSIS; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOCOMPETENT CELL; LARGE CELL LYMPHOMA; LUNG ADENOCARCINOMA; LUNG CARCINOMA; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SQUAMOUS CELL CARCINOMA;

ADENOCARCINOMA; CARCINOMA, SQUAMOUS CELL; DIAGNOSIS, DIFFERENTIAL; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MEMBRANE PROTEINS; PREDICTIVE VALUE OF TESTS; TRANSCRIPTION FACTORS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS;

EID: 84857794792     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2011.173     Document Type: Article

References (51)

1. Shigematsu H, Lin L, Takahashi T, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 2005;97:339-346.
2. Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010;363:1693-1703.
3. Johnson DH, Fehrenbacher L, Novotny WF, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004;22:2184-2191.
4. Scagliotti G, Brodowicz T, Shepherd FA, et al. Treatment-by-histology interaction analyses in three phase III trials show superiority of pemetrexed in nonsquamous non-small cell lung cancer. J Thorac Oncol 2011;6:64-70.
5. Hammerman PS, Sos ML, Ramos AH, et al. Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. Cancer Discov 2011;1:77-87.
6. Weiss J, Sos ML, Seidel D, et al. Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci Transl Med 2010;2:62ra93.
7. Kargi A, Gurel D, Tuna B. The diagnostic value of TTF-1, CK 5/6, and p63 immunostaining in classification of lung carcinomas. Appl Immunohistochem Mol Morphol 2007;15:415-420.
8. Mukhopadhyay S, Katzenstein AL. Subclassification of non-small cell lung carcinomas lacking morphologic differentiation on biopsy specimens: Utility of an immunohistochemical panel containing TTF-1, napsin A, p63, and CK5/6. Am J Surg Pathol 2011;35: 15-25.
9. Rekhtman N, Ang DC, Sima CS, et al. Immunohistochemical algorithm for differentiation of lung adenocarcinoma and squamous cell carcinoma based on large series of whole-tissue sections with validation in small specimens. Mod Pathol 2011;24: 1348-1359.
10. Wu M, Szporn AH, Zhang D, et al. Cytology applications of p63 and TTF-1 immunostaining in differential diagnosis of lung cancers. Diagn Cytopathol 2005;33:223-227.
11. Terry J, Leung S, Laskin J, et al. Optimal immunohistochemical markers for distinguishing lung adenocarcinomas from squamous cell carcinomas in small tumor samples. Am J Surg Pathol 2010;34: 1805-1811.
12. Au NH, Gown AM, Cheang M, et al. P63 expression in lung carcinoma: a tissue microarray study of 408 cases. Appl Immunohistochem Mol Morphol 2004;12: 240-247.
13. Del Vescovo V, Cantaloni C, Cucino A, et al. miR-205 expression levels in nonsmall cell lung cancer do not always distinguish adenocarcinomas from squamous cell carcinomas. Am J Surg Pathol 2011;35:268-275.
14. Bishop JA, Benjamin H, Cholakh H, et al. Accurate classification of non-small cell lung carcinoma using a novel microRNA-based approach. Clin Cancer Res 2010;16:610-619.
15. Kalhor N, Zander DS, Liu J. TTF-1 and p63 for distinguishing pulmonary small-cell carcinoma from poorly differentiated squamous cell carcinoma in previously pap-stained cytologic material. Mod Pathol 2006;19:1117-1123.
16. Pelosi G, Pasini F, Olsen Stenholm C, et al. P63 immunoreactivity in lung cancer: yet another player in the development of squamous cell carcinomas? J Pathol 2002;198:100-109.
17. Tsuta K, Tanabe Y, Yoshida A, et al. Utility of immunohistochemical markers including novel markers (desmocollin-3, glypican 3, S100A2, S100A7, and sox-2) for differential diagnosis of squamous cell carcinoma from adenocarcinoma of the lung. J Thorac Oncol 2011;6:1190-1199.
18. Yoshida A, Tsuta K, Watanabe S, et al. Frequent ALK rearrangement and TTF-1/p63 co-expression in lung adenocarcinoma with signet-ring cell component. Lung Cancer 2011;72:309-315.
19. Chilosi M, Zamo A, Brighenti A, et al. Constitutive expression of DeltaN-p63alpha isoform in human thymus and thymic epithelial tumours. Virchows Arch 2003;443:175-183.
20. Gualco G, Weiss LM, Bacchi CE. Expression of p63 in anaplastic large cell lymphoma but not in classical Hodgkin's lymphoma. Hum Pathol 2008;39: 1505-1510.
21. Hallack Neto AE, Siqueira SA, Dulley FL, et al. p63 protein expression in high risk diffuse large B-cell lymphoma. J Clin Pathol 2009;62:77-79.
22. Hedvat CV, Teruya-Feldstein J, Puig P, et al. Expression of p63 in diffuse large B-cell lymphoma. Appl Immunohistochem Mol Morphol 2005;13:237-242.
23. Fukushima N, Satoh T, Sueoka N, et al. Clinicopathological characteristics of p63 expression in B-cell lymphoma. Cancer Sci 2006;97:1050-1055.
24. Park CK, Oh YH. Expression of p63 in reactive hyperplasias and malignant lymphomas. J Korean Med Sci 2005;20:752-758.
25. Suster S, Moran CA. Pleomorphic large cell lymphomas of the mediastinum. Am J Surg Pathol 1996;20: 224-232.
26. Rush WL, Andriko JA, Taubenberger JK, et al. Primary anaplastic large cell lymphoma of the lung: a clinicopathologic study of five patients. Mod Pathol 2000; 13:1285-1292.
27. Murray JG, Breatnach E. Imaging of the mediastinum and hila. Curr Opin Radiol 1992;4:44-52.
28. Di Como CJ, Urist MJ, Babayan I, et al. P63 expression profiles in human normal and tumor tissues. Clin Cancer Res 2002;8:494-501.
29. Nylander K, Vojtesek B, Nenutil R, et al. Differential expression of p63 isoforms in normal tissues and neoplastic cells. J Pathol 2002;198:417-427.
30. Crum CP, McKeon FD. P63 in epithelial survival, germ cell surveillance, and neoplasia. Annu Rev Pathol 2010;5:349-371.
31. Yang A, Kaghad M, Wang Y, et al. P63, a P53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol Cell 1998;2:305-316.
32. Senoo M, Pinto F, Crum CP, et al. p63 is essential for the proliferative potential of stem cells in stratified epithelia. Cell 2007;129:523-536.
33. Sniezek JC, Matheny KE, Westfall MD, et al. Dominant negative p63 isoform expression in head and neck squamous cell carcinoma. Laryngoscope 2004;114: 2063-2072.
34. Massion PP, Taflan PM, Jamshedur Rahman SM, et al. Significance of p63 amplification and overexpression in lung cancer development and prognosis. Cancer Res 2003;63:7113-7121.
35. Hibi K, Trink B, Patturajan M, et al. AIS is an oncogene amplified in squamous cell carcinoma. Proc Natl Acad Sci USA 2000;97:5462-5467.
36. Geddert H, Kiel S, Heep HJ, et al. The role of p63 and deltaNp63 (p40) protein expression and gene amplification in esophageal carcinogenesis. Hum Pathol 2003;34:850-856.
37. Karni-Schmidt O, Castillo-Martin M, HuaiShen T, et al. Distinct expression profiles of p63 variants during urothelial development and bladder cancer progression. Am J Pathol 2011;178:1350-1360.
38. Shih IM, Kurman RJ. P63 expression is useful in the distinction of epithelioid trophoblastic and placental site trophoblastic tumors by profiling trophoblastic subpopulations. Am J Surg Pathol 2004;28: 1177-1183.
39. Pelosi G, Sonzogni A, Papotti M, et al. Different prevalence of transactivating (TA) p63 and non-TAp63 isoforms in pulmonary adenocarcinomas: A useful diagnostic tool. Mod Pathol 2010;23: 411A-412A.
40. Pelosi G, Fabbri A, Rossi G, et al. A two-hit minimalist diagnostic algorithm based on p40 (deltaNp63) and TTF-1 immunostaining upon small biopsy/cellblock samples for differentiating main subtypes of non-small cell lung cancer and sparing material. J Thor Oncol 2011;6:S335-S336.
41. Righi L, Graziano P, Fornari A, et al. Immunohistochemical subtyping of nonsmall cell lung cancer not otherwise specified in fine-needle aspiration cytology: a retrospective study of 103 cases with surgical correlation. Cancer 2011;117:3416-3423.
42. Travis WD, Brambilla E, Muller-Hermelink HK, Harris CC, (Eds). World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart. IARC Press: Lyon, France, 2004.
43. Chilosi M, Poletti V, Murer B, et al. Abnormal re-epithelialization and lung remodeling in idiopathic pulmonary fibrosis: the role of deltaN-p63. Lab Invest 2002;82:1335-1345.
44. Wu M, Orta L, Gil J, et al. Immunohistochemical detection of XIAP and p63 in adenomatous hyperplasia, atypical adenomatous hyperplasia, bronchioloalveolar carcinoma and well-differentiated adenocarcinoma. Mod Pathol 2008;21:553-558.
45. Zamo A, Malpeli G, Scarpa A, et al. Expression of TP73L is a helpful diagnostic marker of primary mediastinal large B-cell lymphomas. Mod Pathol 2005; 18:1448-1453.
46. Pruneri G, Fabris S, Dell'Orto P, et al. The transactivating isoforms of p63 are overexpressed in highgrade follicular lymphomas independent of the occurrence of p63 gene amplification. J Pathol 2005;206: 337-345.
47. Monica V, Ceppi P, Righi L, et al. Desmocollin-3: a new marker of squamous differentiation in undifferentiated large-cell carcinoma of the lung. Mod Pathol 2009;22:709-717.
48. Loo PS, Thomas SC, Nicolson MC, et al. Subtyping of undifferentiated non-small cell carcinomas in bronchial biopsy specimens. J Thorac Oncol 2010;5: 442-447.
49. Nicholson AG, Gonzalez D, Shah P, et al. Refining the diagnosis and EGFR status of non-small cell lung carcinoma in biopsy and cytologic material, using a panel of mucin staining, TTF-1, cytokeratin 5/6, and P63, and EGFR mutation analysis. J Thorac Oncol 2010;5:436-441.
50. Travis WD, Rekhtman N. Pathological diagnosis and classification of lung cancer in small biopsies and cytology: Strategic management of tissue for molecular testing. Semin Respir Crit Care Med 2011;32:22-31.
51. Matoso A, Singh K, Jacob R, et al. Comparison of thyroid transcription factor-1 expression by 2 monoclonal antibodies in pulmonary and nonpulmonary primary tumors. Appl Immunohistochem Mol Morphol 2010;18:142-149.